But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 
Latest 5 articles from heartwire

CURRENT OASIS-7: Doubling the clopidogrel dose in ACS patients undergoing PCI

Posted Oct 22, 2009 at 09:30 AM, EDT by Samuel Goldhaber

The CURRENT OASIS-7 trial published during ESC showed a remarkable reduction in myocardial infarction and in-stent thrombosis for patients whose loading dose of clopidogrel was doubled. With a dataset of over 17,000 patients, the results are remarkable and uptake in cath labs has been rapid. With time, how will the OASIS-7 regimen compare with novel antiplatelet agents and approaches to antiplatelet testing?

See:

CURRENT OASIS-7: Benefit to doubling clopidogrel dose in ACS patients undergoing PCI

1 Comments | Add your own comments | Permalink

Comments

What I think that doubling the dose may causes unavoidable bleeding in the responder. Because still you need some platelet function, for those who are not responding it is wasting of money. So what I suggest, is ,the dose should be platelet -function guided

 
Posted by asuwaidi, Oct 28, 2009 at 10:47 AM, EDT
Reply to this comment

Add your own comments



 


This blog on theheart.org is a sounding board for healthcare providers, clinicians, and researchers, and is not intended to supply answers or advice to patients. We reserve the right to remove posts containing inappropriate language, promotional content, personal agendas or hostile intent, and posts from patients asking for medical advice.

In the interest of promoting a balanced exchange, please disclose any relevant relationships or conflicts of interest when posting your comment.

The views and opinions expressed herein are those of the blogger and do not necessarily reflect those of theheart.org.